Top Page
CSL
(Sydney:CSL)
CSL (CSL) vs. S&P 500 (SPY)
CSL Business Overview & Revenue Model
CSL Financial Statement Overview
| Breakdown | ||||
| Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 14.69B | 19.59B | 14.47B | 10.33B | 9.41B | Gross Profit |
| 7.56B | 9.47B | 7.68B | 5.74B | 5.28B | EBIT |
| 1.84B | 4.36B | 3.94B | 3.11B | 2.76B | EBITDA |
| 4.73B | 5.85B | 3.46B | 2.72B | 2.18B | Net Income Common Stockholders |
| 2.64B | 3.34B | 3.11B | 2.39B | 2.17B |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 1.66B | 2.33B | 15.18B | 1.81B | 1.19B | Total Assets |
| 38.02B | 54.43B | 41.22B | 18.16B | 15.46B | Total Debt |
| 12.18B | 18.37B | 14.04B | 5.81B | 5.99B | Net Debt |
| 10.53B | 16.04B | -1.13B | 4.00B | 4.80B | Total Liabilities |
| 18.62B | 27.65B | 20.02B | 9.74B | 8.94B | Stockholders Equity |
| 17.33B | 23.72B | 21.20B | 8.38B | 6.53B |
| Cash Flow | Free Cash Flow | |||
| 1.51B | 1.35B | 1.90B | 1.97B | 1.16B | Operating Cash Flow |
| 2.81B | 3.87B | 3.62B | 3.65B | 2.57B | Investing Cash Flow |
| -1.26B | -17.61B | -2.26B | -1.68B | -1.41B | Financing Cash Flow |
| -1.28B | 677.92M | 10.58B | -1.41B | -664.30M |
CSL Technical Analysis
CSL Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | AU$54.61B | 27.14 | 25.23% | 0.85% | 10.54% | 38.69% | |
73 Outperform | AU$12.56B | 22.85 | 6.86% | 4.05% | 10.15% | 6.20% | |
64 Neutral | $121.28B | 29.85 | 15.38% | 1.90% | 8.00% | 9.09% | |
52 Neutral | $5.17B | 3.59 | -42.19% | 2.82% | 15.05% | -0.04% |
CSL Earnings Call Summary
CSL Corporate Events
CSL Limited announced the cessation of 12,039 securities due to the lapse of conditional rights, as the conditions were not met or became incapable of being satisfied. This development may impact the company’s capital structure and could have implications for stakeholders regarding the company’s strategic financial management.
CSL Limited announced the cessation of 6,106 conditional rights to securities as the conditions for these rights were not met or became incapable of being satisfied. This announcement may impact CSL’s capital structure and could have implications for stakeholders regarding the company’s financial strategies and market operations.
CSL has responded to the recent announcement by the United States Administration regarding the imposition of reciprocal tariffs on imports. While pharmaceutical products are currently exempt from these tariffs, CSL is closely monitoring the situation to assess any broader impacts. The company is committed to collaborating with the U.S. administration to ensure that American patients continue to have access to its lifesaving medicines.
CSL Limited announced a change in the director’s interest, with Dr. Megan Clark acquiring 200 additional ordinary shares through an on-market transaction. This acquisition increases Dr. Clark’s direct holding to 3,883 ordinary shares, reflecting her continued confidence in the company’s performance and future prospects. This change in director’s interest is a routine update that may reassure stakeholders about the stability and governance of CSL Limited.
CSL Limited announced the cessation of 10,573 securities due to the lapse of conditional rights, as the conditions for these rights have not been met or have become incapable of being satisfied. This development may affect CSL’s issued capital and could have implications for stakeholders, as it reflects changes in the company’s securities management.
CSL Limited has updated its previous announcement regarding the dividend distribution for its ordinary fully paid shares. The update includes details on currency rates and local currency conversions for the dividend related to the six-month period ending December 31, 2024. This announcement is significant for stakeholders as it provides clarity on the financial aspects of the dividend distribution, potentially impacting investor decisions and market perceptions.
CSL Limited announced the issuance of 21,411 unquoted equity securities under an employee incentive scheme, which are subject to transfer restrictions and are not listed on the ASX until the restrictions are lifted. This move is part of CSL’s strategy to incentivize and retain talent, potentially impacting its operational efficiency and market competitiveness.
CSL Limited has announced the application for the quotation of 5,407 ordinary fully paid securities on the Australian Securities Exchange (ASX). These securities are issued under an employee incentive scheme and are not subject to transfer restrictions, indicating a strategic move to enhance employee engagement and potentially improve market liquidity.
CSL Limited announced the issuance of unquoted equity securities as part of an employee incentive scheme. These securities are subject to transfer restrictions and will not be quoted on the ASX until these restrictions are lifted, indicating a strategic move to enhance employee engagement and retention.
CSL Limited announced a change in the shareholding interests of its director, Ms Alison Watkins AM. The change involved the acquisition of 154 Ordinary Shares through the exercise of 154 Rights under the company’s Non-Executive Director Rights Plan. This acquisition was funded by a portion of her Board fee, reflecting an ongoing commitment to align director interests with shareholder value. Such changes in director shareholding could impact perceptions of company stability and governance among stakeholders.
CSL Limited reports a strong financial performance for the first half of the 2025 financial year, with a net profit after tax of $2.01 billion, reflecting a 7% increase on a constant currency basis. The company attributes this growth to robust demand in its CSL Behring segment, particularly in immunoglobulin therapies and haemophilia products. However, the CSL Seqirus segment faced challenges due to significantly low influenza immunization rates affecting vaccine sales. Despite these challenges, CSL continues to make strategic advancements, including its plasma collections and the rollout of new plasmapheresis devices, reinforcing its market position.
CSL has announced its financial results for the half year ending December 31, 2024, showing a 5% increase in total revenue to US$8.483 billion and a 6% increase in net profit after tax (NPAT) to US$2.007 billion. These results reflect the company’s robust performance and strategic focus on enhancing shareholder value. The interim dividend is set at US$1.30 per security, unfranked, underscoring CSL’s strong operational execution and its commitment to returning capital to shareholders.